Rearrangements of the anaplastic lymphoma kinase (ALK) gene are indicative of a distinct subset of non-small-cell lung cancer (NSCLC), characterised by excellent responses to ALK-targeted therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.